مباشر
10x Genomics Blog10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda - Stock TitanFierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series BEndpoints News#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six monthsRoche MediaRoche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical ExecutiveBioPharma DiveCity banks nearly $100M for next-gen RNAi drugsEndpoints NewsIncyte CEO sees $2B Vega deal aiding a post-Jakafi futureClinical OMICsCortical On/Off Switch Provides Sleep Benefits to Awake MiceClinical OMICsGLP-1 Drugs Linked to Lower Rates of Substance Use DisordersEndpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicinesClinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer ResearchClinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental Models
BioWorld ٢٤ أبريل ٢٠٢٦

Jiangsu Carephar Pharmaceutical describes new AT2 receptor agonists

Jiangsu Carephar Pharmaceutical describes new AT2 receptor agonists

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.